CCB International
CCB International (Holdings) Limited, a subsidiary of China Construction Bank Corporation, operates as an investment services firm. Its core business encompasses three primary areas: Pre-IPO, IPO, and Post-IPO, creating a comprehensive investment services value chain. CCB International provides a wide array of services, including sponsoring and underwriting, financial advisory, corporate mergers and acquisitions, restructuring, and additional issuance and placement of shares. The firm also engages in refinancing for listed companies, direct investment, asset management, securities brokerage, market research, and investment consultancy, catering to diverse client needs in the financial market.
OrbusNeich Medical is a China-based global medical device manufacturer specializing in endovascular interventional instruments. Established in 2001 with its first research base, the company has achieved significant growth and was listed on the Hong Kong Exchange in 2022. As of 2023, its largest revenue segment comes from Japan, accounting for 24.7% of total revenue, followed closely by Europe, the Middle East, and Africa at 23.6%. The Asia-Pacific region and the United States contribute to the remainder of its revenue. OrbusNeich's primary product segment is coronary interventional medical devices, including scoring balloons, non-compliant balloons, and stents, which together comprise 82.7% of its total revenue.
Hinova Pharmaceuticals Inc. is a drug discovery and development company focused on addressing unmet medical needs in China. Founded in 2013 and headquartered in Chengdu, with additional branches in Kowloon, Hong Kong, Houston, Texas, and Southbank, Australia, the company operates as a subsidiary of Haisco Pharmaceutical Group Co., Ltd. Hinova specializes in innovative drug research and development, utilizing advanced methodologies such as medicinal chemistry, biological screening, and clinical research. Its primary products include HC-1119, an androgen receptor antagonist, and HC-1102, an androgen receptor inhibitor, aimed at treating advanced prostate cancer and breast cancer.
InnoCare Pharma Limited is a biopharmaceutical company focused on developing innovative treatments for cancer and autoimmune diseases. Founded in 2015 and headquartered in Wanchai, Hong Kong, InnoCare operates additional offices in major cities across China and in Cambridge, Massachusetts. The company is advancing several clinical programs, including Orelabrutinib, which targets various B-cell malignancies and is currently undergoing registrational trials. It is also developing ICP-192, a pan-inhibitor of fibroblast growth factor receptor, and ICP-105, which targets FGFR4 in advanced hepatocellular carcinoma. InnoCare's preclinical pipeline includes promising candidates aimed at treating specific cancer types and autoimmune disorders. The firm is supported by a highly qualified scientific team and a specialized advisory board, reinforcing its commitment to pushing the boundaries of drug innovation and improving patient outcomes.
Green Leader Holdings Group Ltd, is a mineral exploration and development company currently focused in Mongolia. Our principal business is focused on strategic investments in the mining sectors. The shares of the Company are listed on the main board of the Stock Exchange of Hong Kong Limited under stock code 61.